Nothing Special   »   [go: up one dir, main page]

NO20033364L - Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen - Google Patents

Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen

Info

Publication number
NO20033364L
NO20033364L NO20033364A NO20033364A NO20033364L NO 20033364 L NO20033364 L NO 20033364L NO 20033364 A NO20033364 A NO 20033364A NO 20033364 A NO20033364 A NO 20033364A NO 20033364 L NO20033364 L NO 20033364L
Authority
NO
Norway
Prior art keywords
pathogen
isolation
identification
production
antigens specifically
Prior art date
Application number
NO20033364A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033364D0 (no
Inventor
Andreas Meinke
Eszter Nagy
Uwe Von Ahsen
Christoph Klade
Tamas Henics
Wolfgang Zauner
Duc Bui Minh
Oresta Vytvytska
Hildegard Etz
Agnieszka Dryla
Thomas Weichhart
Martin Hafner
Brigitte Tempelmaier
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Publication of NO20033364D0 publication Critical patent/NO20033364D0/no
Publication of NO20033364L publication Critical patent/NO20033364L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20033364A 2001-01-26 2003-07-25 Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen NO20033364L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0013001A AT410798B (de) 2001-01-26 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
PCT/EP2002/000546 WO2002059148A2 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen

Publications (2)

Publication Number Publication Date
NO20033364D0 NO20033364D0 (no) 2003-07-25
NO20033364L true NO20033364L (no) 2003-09-24

Family

ID=3636418

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033364A NO20033364L (no) 2001-01-26 2003-07-25 Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen

Country Status (24)

Country Link
US (4) US7968297B2 (pl)
EP (6) EP2322539A3 (pl)
JP (2) JP2004531476A (pl)
KR (4) KR20090101973A (pl)
CN (2) CN101492496A (pl)
AT (2) AT410798B (pl)
AU (3) AU2002247641B8 (pl)
BR (1) BR0207067A (pl)
CA (2) CA2436057C (pl)
CZ (1) CZ20032201A3 (pl)
DE (1) DE60207194T2 (pl)
DK (1) DK1355930T3 (pl)
ES (1) ES2252438T3 (pl)
HU (1) HUP0402048A3 (pl)
IL (4) IL157082A0 (pl)
IS (1) IS6895A (pl)
MX (1) MXPA03006702A (pl)
NO (1) NO20033364L (pl)
NZ (4) NZ540764A (pl)
PL (2) PL214482B1 (pl)
RU (1) RU2289817C2 (pl)
SK (1) SK10492003A3 (pl)
WO (1) WO2002059148A2 (pl)
ZA (1) ZA200305764B (pl)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265488T3 (es) 2001-01-03 2007-02-16 Epitopix Llc Composiciones inmunizantes y metodos de uso.
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
MXPA03011701A (es) * 2001-06-15 2004-12-06 Nhibitex Inc Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus.
GB0200865D0 (en) * 2002-01-16 2002-03-06 Univ Bristol Method
GB2387600A (en) * 2002-04-19 2003-10-22 Pantherix Ltd Pantothenate kinase
CA2484335A1 (en) * 2002-10-03 2004-04-15 Intercell Ag Use of molecules which interact with the haptoglobin receptor ligand binding
DK1601770T3 (da) * 2003-03-04 2009-11-02 Intercell Ag Streptococcus pyogenes antigener
US7628994B2 (en) 2003-03-31 2009-12-08 Intercell Ag S. epidermidis antigens
EP2314719A1 (en) 2003-04-15 2011-04-27 Intercell AG S. pneumoniae antigens
WO2004094467A2 (en) * 2003-04-22 2004-11-04 Intercell Ag H. pylori antigens
EP2289907A3 (en) * 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae antigens I + II
EP1629005A2 (en) * 2003-05-30 2006-03-01 Intercell AG Enterococcus antigens
RU2257217C2 (ru) * 2003-07-08 2005-07-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Гипериммунный тканевой препарат
WO2005009378A2 (en) * 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
KR20060065643A (ko) * 2003-07-24 2006-06-14 머크 앤드 캄파니 인코포레이티드 스타필로코쿠스 아우레우스에 대한 방어 면역 반응을유도하는 폴리펩타이드
WO2005028665A2 (en) 2003-09-19 2005-03-31 Epitopix, Llc Campylobacter polypeptides and methods of use
CA2555342A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
EP1725255A4 (en) * 2004-02-27 2007-07-11 Merck & Co Inc POLYPEPTIDES FOR INDUCING AN IMMUNE RESPONSE PROTECTING AGAINST STAPHYLOCOCCUS AUREUS
JP2005278537A (ja) * 2004-03-30 2005-10-13 Dai Ichi Seiyaku Co Ltd 新規ポリペプチド
WO2005103073A2 (en) * 2004-04-27 2005-11-03 Intercell Ag Td antigens
WO2006065272A2 (en) 2004-05-21 2006-06-22 Idaho Research Foundation, Inc. Methods for altering acetic acid production and enhancing cell death in bacteria
JP2008500043A (ja) * 2004-05-25 2008-01-10 メルク　エンド　カムパニー　インコーポレーテッド 黄色ブドウ球菌に対する感染防御免疫応答を誘導するためのポリペプチド
US20090317412A1 (en) * 2004-06-04 2009-12-24 Alexander Jeffery L Induction of an immune response against streptococcus pneumoniae polyaccharides
FR2871237B1 (fr) * 2004-06-08 2011-03-11 Abag Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes
FR2871159A1 (fr) * 2004-06-08 2005-12-09 Abag Sa Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative
WO2007018482A2 (en) * 2004-07-06 2007-02-15 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
US20080095792A1 (en) * 2004-09-17 2008-04-24 Anderson Annaliesa S Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus
KR101505496B1 (ko) 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
US8445000B2 (en) 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
DE602005015605D1 (de) * 2004-10-29 2009-09-03 Intercell Ag Hcv impfstoff für chronische hcv patienten
CN101432017B (zh) 2005-01-21 2011-12-21 默沙东公司 用于诱导针对金黄色葡萄球菌的保护性免疫应答的多肽
AU2006206234B2 (en) 2005-01-21 2012-01-12 Epitopix, Llc Yersinia spp. polypeptides and methods of use
JP2008532935A (ja) 2005-02-14 2008-08-21 エピトピックス，リミティド ライアビリティ カンパニー 黄色ブドウ球菌由来のポリペプチド及び使用方法
EP1869461A1 (en) * 2005-04-04 2007-12-26 Viventia Biotech Inc. Method and system for identification of antigen
WO2006121664A2 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
US20070003954A1 (en) * 2005-05-12 2007-01-04 The Board Of Regents Of The University Of Texas System Protein and antibody profiling using small molecule microarrays
EP1904520A2 (en) * 2005-07-14 2008-04-02 Bharat Biotech International Limited A vaccine for staphylococcal infections
EP2368569A3 (en) * 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
WO2008031133A2 (en) * 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
US20080102067A1 (en) * 2006-10-25 2008-05-01 Cook Mark E Immunogenic composition
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
EP1935984A1 (en) * 2006-12-20 2008-06-25 Unilever N.V. Screening method for the identification of a preservative
AU2008251982A1 (en) 2007-01-24 2008-11-20 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus epidermidis
WO2008115415A2 (en) * 2007-03-19 2008-09-25 Merck & Co., Inc Polypeptides for inducing a protective immune response against staphylococcus epidermidis
CN101883782A (zh) * 2007-06-18 2010-11-10 英特塞尔股份公司 衣原体抗原
KR101661946B1 (ko) 2007-08-31 2016-10-05 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
ES2436498T3 (es) * 2007-10-18 2014-01-02 Unilever N.V. Método para producir un agente espumante
CN101458255B (zh) * 2007-12-14 2013-03-06 武汉大学 丙型肝炎病毒包膜抗原夹心法试剂盒及检测方法
US20090196852A1 (en) * 2008-02-04 2009-08-06 Watkinson D Tobin Compositions and methods for diagnosing and treating immune disorders
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
BRPI0909664A2 (pt) 2008-03-17 2019-09-24 Intercell Ag peptídios protetores contra s. pneumoniae e composições, métodos e usos relacionados com os mesmos
WO2009158682A2 (en) * 2008-06-27 2009-12-30 Watkinson D Tobin Compositions and methods for diagnosing and treating pathogenic disorders
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2344189B1 (en) * 2008-09-30 2018-05-30 University of Maryland, Baltimore Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
CN102333540B (zh) * 2008-10-06 2015-04-22 芝加哥大学 与细菌eap、emp和/或adsa蛋白相关的组合物和方法
MX2011004080A (es) * 2008-10-16 2011-07-28 Unilever Nv Solucion de hidrofobina conteniendo antiespumante.
MX2011005578A (es) 2008-11-26 2011-06-30 Merck Sharp & Dohme Polipeptidos para inducir una respuesta inmune protectora contra staphylococcus aureus.
JP2012509665A (ja) 2008-11-26 2012-04-26 メルク・シャープ・エンド・ドーム・コーポレイション スタフィロコッカス・アウレウス（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対する防御免疫応答を誘導するポリペプチド
RU2371201C1 (ru) * 2008-12-15 2009-10-27 Гурий Петрович Ступаков Способ лечения хронических заболеваний
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
KR20160114744A (ko) * 2009-03-23 2016-10-05 이피토픽스, 엘엘씨 폴리펩티드 및 그람 양성 폴리펩티드를 함유하는 면역 조성물 및 사용 방법
SI3281947T1 (sl) * 2009-04-03 2020-07-31 The University Of Chicago Sestave in metode v zvezi z variantami proteina A (SPA)
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
RU2508126C2 (ru) * 2009-04-14 2014-02-27 Новартис Аг Композиции для иммунизации против staphylococcus aureus
CA2704702C (en) * 2009-06-02 2018-06-12 Unilever Plc Aerated baked products
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
SG10201707084SA (en) 2009-06-22 2017-10-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
BR112012029521A2 (pt) 2010-05-05 2018-03-06 New York University leucocidinas do staphylococcus aureus, composições terapêuticas, e aplicações das mesmas.
EP2588120B1 (en) 2010-07-02 2017-11-15 The University of Chicago Compositions and methods related to protein a (spa) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2593133A4 (en) 2010-07-13 2014-11-26 Merck Sharp & Dohme STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED ON IT
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
CN102558316B (zh) * 2010-12-30 2015-07-01 上海雅心生物技术有限公司 高稳定性的具抗体结合能力的重组蛋白a及其生产
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
ES2609817T3 (es) 2011-06-19 2017-04-24 New York University Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
EP2720714B1 (en) 2011-06-19 2018-07-18 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions
WO2013066731A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2451 protein
KR102336895B1 (ko) 2012-02-20 2021-12-08 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
US9968668B2 (en) 2012-04-26 2018-05-15 The University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
RU2526497C2 (ru) * 2012-10-31 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохарнения и социального развития Российской Федерации Способ определения генотипов золотистого стафилококка
JP6694269B2 (ja) * 2012-11-06 2020-05-13 メディミューン，エルエルシー Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
EP2935324B1 (en) * 2012-12-20 2019-10-23 MorphoSys AG Anti-staphylococcal antibodies
CN103965336B (zh) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
EP2990423B1 (en) * 2013-04-25 2018-04-18 AbTLAS Co., Ltd. Method for refining protein including self-cutting cassette and use thereof
AU2014314222B2 (en) * 2013-08-28 2018-05-24 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement C5
KR20160068744A (ko) 2013-08-28 2016-06-15 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
CN104558196A (zh) * 2013-10-15 2015-04-29 温州医科大学 基于HBcAg载体的沙眼衣原体主要外膜蛋白表位疫苗及其用途
RU2542396C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ и набор для ускоренной лабораторной диагностики коклюшной инфекции
EP4227685A3 (en) * 2013-12-03 2024-02-28 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
CN103694323B (zh) * 2013-12-09 2017-01-18 成都欧林生物科技股份有限公司 金黄色葡萄球菌MntC重组蛋白及其制备方法和应用
US10100093B2 (en) 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
EP3160492A4 (en) 2014-06-30 2018-01-03 Murdoch Childrens Research Institute Helicobacter therapeutic
CN104569386B (zh) * 2014-12-10 2016-05-11 中国水产科学研究院淡水渔业研究中心 一种罗非鱼源无乳链球菌elisa快速检测试剂盒及其检测方法
WO2016096787A1 (en) * 2014-12-17 2016-06-23 F. Hoffmann-La Roche Ag Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase
US10781246B2 (en) 2015-06-05 2020-09-22 New York University Compositions and methods for anti-staphylococcal biologic agents
CN108138158B (zh) 2015-09-25 2021-11-09 豪夫迈·罗氏有限公司 可溶性分选酶a
WO2017050874A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Process for producing thioesters employing a sortase a
WO2017050872A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
US11746135B2 (en) 2015-11-27 2023-09-05 Masarykova Univerzita Thermostable FGF2 polypeptide, use thereof
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US10504742B2 (en) * 2017-05-31 2019-12-10 Asm Ip Holding B.V. Method of atomic layer etching using hydrogen plasma
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
PH12020551241A1 (en) 2018-02-12 2021-04-19 Inimmune Corp Toll-like receptor ligands
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
RU2689161C1 (ru) * 2018-10-04 2019-05-24 Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения бактериальных антигенов
CN111110838A (zh) * 2019-12-24 2020-05-08 华南师范大学 一种罗非鱼无乳链球菌疫苗及其制备方法
CN111808977B (zh) * 2020-07-23 2023-06-27 清华大学深圳国际研究生院 一种由snp所引起利福平类抗生素耐药的抗性基因的特异性引物的设计方法及检测方法
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用
KR102306010B1 (ko) * 2021-04-07 2021-09-27 씨제이제일제당 (주) 신규한 분지쇄아미노산 투과효소 변이체 및 이를 이용한 l-발린 생산 방법
KR102281369B1 (ko) * 2021-04-07 2021-07-22 씨제이제일제당 (주) 신규한 디히드로리포일 아세틸기전이효소 변이체 및 이를 이용한 l-발린 생산 방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2955014B2 (ja) * 1989-03-09 1999-10-04 アメリカン・サイアナミド・カンパニー 分類できないヘモフイルス・インフルエンザエに対するワクチン
US5980908A (en) 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
US5456907A (en) 1992-01-10 1995-10-10 Helene Curtis, Inc. Cysteamine permanent wave composition and method
US5700928A (en) * 1995-10-16 1997-12-23 Smithkline Beecham, P.L.C. Polynucleotide encoding saliva binding protein
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
WO1999030151A1 (en) * 1997-12-05 1999-06-17 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Method and cells to screen combinatorial libraries
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
CA2329986A1 (en) * 1998-04-30 1999-11-11 Dolores Cahill New method for the selection of clones of an expression library involving rearraying
EP1090111A1 (en) 1998-06-25 2001-04-11 Institut Pasteur Exhaustive analysis of viral protein interactions by two-hybrid screens and selection of correctly folded viral interacting polypeptides
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
AT407643B (de) * 1999-02-01 2001-05-25 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Verfahren zur selektion und herstellung von vakzin- und diagnostika-präparationen
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
ES2402878T3 (es) * 1999-05-05 2013-05-10 Phylogica Limited Aislamiento de moduladores biológicos a partir de colecciones de fragmentos génicos biodiversos
US8034571B1 (en) * 1999-08-06 2011-10-11 Oragenics, Inc. Microbial polynucleotides expressed during infection of a host
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1268774A2 (en) 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
PL211036B1 (pl) 2000-06-08 2012-04-30 Intercell Biomedizinische Forschungs & Entwicklungs Ag Zastosowanie cząsteczki immunostymulującego kwasu oligodezoksynukleinowego (ODN) i zawierająca ją kompozycja
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
MXPA03011701A (es) 2001-06-15 2004-12-06 Nhibitex Inc Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus.
ATE542829T1 (de) 2001-08-02 2012-02-15 Univ Sheffield Impfstoff
KR20060065643A (ko) 2003-07-24 2006-06-14 머크 앤드 캄파니 인코포레이티드 스타필로코쿠스 아우레우스에 대한 방어 면역 반응을유도하는 폴리펩타이드
EP1976066B1 (en) 2005-06-13 2015-08-12 BlackBerry Limited Electrical connector and system for a component in an electronic device

Also Published As

Publication number Publication date
ZA200305764B (en) 2004-07-26
KR20080107477A (ko) 2008-12-10
DK1355930T3 (da) 2006-03-06
IL211037A0 (en) 2011-04-28
IL211037A (en) 2013-07-31
AU2002247641B8 (en) 2008-03-13
AU2010200549A1 (en) 2010-03-04
US8323660B2 (en) 2012-12-04
PL392964A1 (pl) 2011-01-03
US8715688B2 (en) 2014-05-06
US7968297B2 (en) 2011-06-28
EP1355930A2 (en) 2003-10-29
IL211038A0 (en) 2011-04-28
CN101492496A (zh) 2009-07-29
US20050037444A1 (en) 2005-02-17
WO2002059148A2 (en) 2002-08-01
EP2322539A3 (en) 2011-09-07
AU2007234519A1 (en) 2007-12-13
JP5053933B2 (ja) 2012-10-24
KR100901915B1 (ko) 2009-06-10
CN1649894A (zh) 2005-08-03
US20080038287A1 (en) 2008-02-14
IL186706A0 (en) 2008-02-09
WO2002059148A9 (en) 2002-10-31
PL209115B1 (pl) 2011-07-29
RU2289817C2 (ru) 2006-12-20
KR20090101973A (ko) 2009-09-29
RU2003125967A (ru) 2005-03-10
NZ527440A (en) 2006-02-24
HUP0402048A3 (en) 2010-01-28
ES2252438T3 (es) 2006-05-16
CA2436057A1 (en) 2002-08-01
BR0207067A (pt) 2004-06-15
WO2002059148A3 (en) 2003-07-31
KR20080029016A (ko) 2008-04-02
JP2004531476A (ja) 2004-10-14
EP2319861A1 (en) 2011-05-11
PL367125A1 (pl) 2005-02-21
EP2322539A2 (en) 2011-05-18
EP2412722A1 (en) 2012-02-01
EP1630172A3 (en) 2006-05-03
HUP0402048A2 (hu) 2005-01-28
SK10492003A3 (sk) 2004-07-07
AU2002247641B2 (en) 2007-08-23
EP1630172B1 (en) 2015-06-10
KR20030082574A (ko) 2003-10-22
WO2002059148A8 (en) 2003-01-16
PL214482B1 (pl) 2013-08-30
EP1630172A2 (en) 2006-03-01
US7771728B2 (en) 2010-08-10
AU2007234519B2 (en) 2009-11-12
NO20033364D0 (no) 2003-07-25
IL186706A (en) 2010-12-30
ATE309268T1 (de) 2005-11-15
DE60207194D1 (de) 2005-12-15
CZ20032201A3 (en) 2004-03-17
KR100851728B1 (ko) 2008-08-11
EP1355930B1 (en) 2005-11-09
JP2008291035A (ja) 2008-12-04
EP1616876A3 (en) 2006-04-12
NZ565349A (en) 2009-07-31
NZ551802A (en) 2008-04-30
IS6895A (is) 2003-07-25
ATA1302001A (de) 2002-12-15
IL157082A0 (en) 2004-02-08
AT410798B (de) 2003-07-25
NZ540764A (en) 2008-03-28
US20130034575A1 (en) 2013-02-07
US20110020402A1 (en) 2011-01-27
EP1616876A2 (en) 2006-01-18
CA2792244A1 (en) 2002-08-01
DE60207194T2 (de) 2006-08-03
MXPA03006702A (es) 2005-04-08
CA2436057C (en) 2012-12-18

Similar Documents

Publication Publication Date Title
NO20033364L (no) Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen
ATE542829T1 (de) Impfstoff
BR0206566A (pt) Arranjo de antìgeno molecular
NO20025838D0 (no) Antigene polypeptider
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
ATE384793T1 (de) Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
DE60229659D1 (de) Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
CY1105947T1 (el) Νουκλεϊνικα οξεα και πρωτεϊνες του γονιδιου mhp3 του mycoplasma hyopneumoniae και χρησεις αυτων
WO2007030771A3 (en) Targeted identification of immunogenic peptides
WO2004073604A3 (en) Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
WO2003074003A3 (en) Immunogens for treatment of neoplastic and infectious disease

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: VALNEVA AUSTRIA GMBH, AT

FC2A Withdrawal, rejection or dismissal of laid open patent application